Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eribulin + sintilimab
- Development stage
- Unknown
- Lead developer
- The Fifth Medical Center of the PLA General Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
eribulin + sintilimab is a combination therapy being investigated for the treatment of metastatic triple-negative breast cancer (mTNBC). Eribulin is a synthetic macrocyclic ketone analogue of halichondrin B that functions as a microtubule dynamics inhibitor. It binds to high-affinity sites on the growing ends of microtubules, leading to cell cycle arrest in the G2/M phase and subsequent apoptosis. Sintilimab is a fully human IgG4 monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor. By blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2), sintilimab restores T-cell mediated anti-tumor immunity. This combination is being evaluated in Phase II clinical trials, such as those led by Beijing 302 Hospital, to determine if the cytotoxic effects of eribulin can enhance the efficacy of immune checkpoint blockade in advanced breast cancer patients.
- Brand names
- HalavenTyvyt
- Other names
- eribulin mesylatesintilimab injectionanti-PD-1 antibodyanti-PD1 antibodyanti-PD 1 antibody
02
Targets
TUBB1 (β-tubulin 1)PDCD1 (Programmed cell death protein 1 receptor)CYP3A4 (Cytochrome P450 3A4)
Beyond the preview
Go deeper on eribulin + sintilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eribulin + sintilimab.